The estimated Net Worth of Sachs Group Incgoldman Sach... is at least $239 Million dollars as of 8 November 2023. Sachs Sach owns over 72,874 units of Panbela Therapeutics stock worth over $139,284 and over the last 21 years Sachs sold PBLA stock worth over $239,049,217.
Sign up
Sachs Sach PBLA stock SEC Form 4 insiders trading
Sachs has made over 48 trades of the Panbela Therapeutics stock since 2005, according to the Form 4 filled with the SEC. Most recently Sachs sold 72,874 units of PBLA stock worth $51,741 on 8 November 2023.
The largest trade Sachs's ever made was selling 5,243,185 units of Panbela Therapeutics stock on 17 May 2012 worth over $197,038,892. On average, Sachs trades about 98,247 units every 72 days since 2003. As of 8 November 2023 Sachs still owns at least 397,954 units of Panbela Therapeutics stock.
You can see the complete history of Sachs Sach stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Sachs Sach's mailing address?
Sachs's mailing address filed with the SEC is 200 WEST STREET200 WEST STREET, , NEW YORKNEW YORK, NYNY, 1028210282.
Insiders trading at Panbela Therapeutics
Over the last 4 years, insiders at Panbela Therapeutics have traded over $51,741 worth of Panbela Therapeutics stock and bought 406,888 units worth $0 . The most active insiders traders include Sachs Group Incgoldman Sach..., Donald Robert Schemel, and Michael T. Cullen. On average, Panbela Therapeutics executives and independent directors trade stock every 67 days with the average trade being worth of $27,986. The most recent stock trade was executed by Sachs Group Incgoldman Sach... on 8 November 2023, trading 72,874 units of PBLA stock currently worth $51,741.
What does Panbela Therapeutics do?
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
What does Panbela Therapeutics's logo look like?
Complete history of Sachs Sach stock trades at Ambarella Inc, Benefitfocus Inc, Endurance International Inc, Extraction Oil & Gas Inc, Meta Platforms Inc, Moneygram International, MYR Inc, Prime Resources Corp, T2 Biosystems Inc, Tiptree Inc, Viveve Medical Inc, Aramark, Core Laboratories Inc, CVR Inc, Dollar General, Enlink Midstream, Hexcel, Hyatt Hotels, Openlane, Kinder Morgan Inc, Lazard, MRC Global Inc, Mesa Air, Rekor Systems Inc, Prosight Global Inc, Kingswood Acquisition, and Panbela Therapeutics
Panbela Therapeutics executives and stock owners
Panbela Therapeutics executives and other stock owners filed with the SEC include:
-
Dr. Jennifer K. Simpson C.R.N.P., CRNP, M.S.N., Ph.D.,
CEO, Pres & Director -
Susan Horvath,
VP of Fin., CFO, Sec. & Treasurer -
Dr. Elizabeth Bruckheimer Ph.D.,
VP & Chief Scientific Officer -
Dr. Suzanne Gagnon,
Chief Medical Officer & Director -
Tammy Groene,
VP of Operations -
Dr. Thomas X. Neenan Ph.D.,
Co-Founder & Chief Scientific Officer -
Suzanne Gagnon,
Director -
Paul W. Schaffer,
Director -
Jeffrey S Mathiesen,
Director -
Susan Horvath,
V.P. of Finance & CFO -
Michael T. Cullen,
Director -
Jennifer K. Simpson,
President and CEO -
Donald Robert Schemel,
Director -
Arthur Fratamico,
Director -
Sachs Group Incgoldman Sach...,
-
Jeffrey E. Jacob,
Director -
Daniel Donovan,
Director